getagozumab (GMA301) / Gmax Biopharm - LARVOL DELTA

Emerging biologics for the treatment of pulmonary arterial hypertension. (PubMed, J Drug Target) - "Here, we have discussed sotatercept, a TGF-β ligand trap, which is reported to reverse vascular remodeling and reduce PVR with an improved 6-minute walk distance (6-MWDT). We also elaborated on other biologics including BMP9 ligand and anti-gremlin1 antibody, anti-OPG antibody, and getagozumab monoclonal antibody and cell-based therapies. Overall, recent literature suggests that biologics hold excellent promise as a safe and effective alternative to currently used PAH therapeutics."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • TGFB1

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Gmax Biopharm LLC.; N=36 ➔ 48; Trial completion date: Jun 2022 ➔ Jun 2023; Trial primary completion date: Sep 2021 ➔ Oct 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Completed; Sponsor: Gmax Biopharm Australia Pty Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Active, not recruiting; Sponsor: Gmax Biopharm Australia Pty Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Hypertension • Pulmonary Arterial Hypertension

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Gmax Biopharm Australia Pty Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hypertension • Pulmonary Arterial Hypertension

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: Gmax Biopharm Australia Pty Ltd.

Clinical • New P1 trial • Hypertension • Pulmonary Arterial Hypertension

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Gmax Biopharm LLC.

Clinical • New P1 trial • Hypertension • Pulmonary Arterial Hypertension